J-HOTATE Association Exhibits at Seafood Expo Global in Spain to appeal premium and fresh Japanese scallops
15.4.2024 14:00:00 EEST | Business Wire | Press release
Japan Scallop Export Promotion Association (“J-HOTATE Association”), which aims to expand the export of Japanese scallops, will be presenting the Japanese scallops to European markets at the Seafood Expo Global, which will be held in Barcelona, Spain, from April 23rd to April 25th, 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415920416/en/
Japanese Scallop - A Sustainable Gastronomic Delight (Photo: Business Wire)
Japanese scallops (we say HOTATE [Hoh-Tah-Teh]) are highly accredited for their flavor, size, and quality. Fresh scallops can be enjoyed year-round under environmentally friendly farming/harvesting methods and the advanced technology to maintain freshness—both of which are unique to Japan. Especially in Hokkaido, Aomori, Iwate, and Miyagi where scallops are produced, local ocean currents provide highly rich nutrients, boasting one of the world’s largest landings of scallops.
Scallops are also known as a healthy seafood. They are rich in nutrients such as vitamin B1, which is effective in alleviating fatigue and improving concentration, and taurine, which is known to improve heart and liver function and help to prevent diabetes. Furthermore, scallops are high in protein and low in calories, making them fit to be a superfood.
Japan is unique to other parts of the world in that the proximity of fishing grounds and ports allows for scallops to be processed and distributed immediately after they are caught, and it has become a common custom in Japan for scallops to be eaten raw. Today, scallops are rapidly frozen right after landing, allowing overseas distribution while maintaining quality.
Exports of Japanese scallop products from Japan to other countries reached a record high of 94.5 billion JPY (approx. 128,000 tons in weight) in 2022, surpassing double its value (over 1.6 times in weight) of that of 2020, when markets stalled due to COVID-19.
|
Export Data of Japanese Scallops (worldwide) |
|||||||||
|
(Units: tons/millions JPY/kg) |
|||||||||
|
2020 |
2021 |
2022 |
|||||||
|
Weight |
Amount |
PPU |
Weight |
Amount |
PPU |
Weight |
Amount |
PPU |
|
|
Raw |
13,990 |
5,090 |
364 |
19,597 |
8,173 |
417 |
16,356 |
9,512 |
582 |
|
Dried |
1,167 |
7,154 |
6,128 |
994 |
5,967 |
6,001 |
454 |
3,914 |
8,628 |
|
Frozen |
63,556 |
26,216 |
412 |
96,392 |
55,877 |
580 |
111,392 |
81,099 |
728 |
|
Total |
78,713 |
38,460 |
489 |
116,983 |
70,018 |
599 |
128,203 |
94,526 |
737 |
|
Source: J-HOTATE Association |
|||||||||
The association has participated in the Seafood Expo in Boston and Singapore and received positive reactions from local firms of North America and Asian countries interested in connecting with Japanese scallop suppliers.
Our goals with the first exhibition in Europe are to increase the export of Japanese scallops and promote the traditional Japanese "eating raw" culture to taste the fullness of scallops' rich nutritional value. The booth will include a business meeting space, introduction of Japanese scallop products and production areas, as well as showing samples of scallops at regular and frozen temperatures, and providing tasting samples of scallops, shipped straight from Japan in Sushi/Sashimi and fried styles.
[Exhibit Information]
Event: Seafood Expo Global (https://www.seafoodexpo.com/global/)
Booth Number: 1F701 (Hall 1)
Date: April 23–April 25, 2024
Venue: FIRA BARCELONA GRAN VIA VENUE
About Japan Scallop Export Promotion Association (“J-HOTATE Association”)
The Japan Scallop Export Promotion Association (J-HOTATE Association) was incorporated in October 2023, with the aim of expanding exports of Japanese scallop products with high quality and healthy flavours through sustainable cultivation. The J-HOTATE Association is currently composed of seventy-four members, including producers (fishery cooperative associations), processors and fisheries-related distributors of Japan and traders. https://j-hotate.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240415920416/en/
Contact information
For Media Inquiry:
J-HOTATE Association PR Office (Asahi Agency)
j-hotate@asahi-ag.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
